Labcorp Holdings Inc
LH240.340USD
+10.740+4.68%
Cierre 04/29, 16:00（ET）Cotizaciones retrasadas 15 min
20.04BCap. mercado
26.87P/E TTM
Más Datos de Labcorp Holdings Inc Compañía
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Información de la empresa
Código de la empresaLH
Nombre de la empresaLabcorp Holdings Inc
Fecha de salida a bolsaApr 24, 1991
Fundada en2024
Director ejecutivoMr. Adam H. Schechter
Número de empleados70000
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 24
Dirección358 S Main St
CiudadBURLINGTON
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal27215
Teléfono13362291127
Sitio Webhttps://www.labcorp.com/
Código de la empresaLH
Fecha de salida a bolsaApr 24, 1991
Fundada en2024
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
105.07K
+19.15%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
32.07K
+10.11%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
13.17K
-5.65%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Richelle P. Parham
Ms. Richelle P. Parham
Independent Director
Independent Director
9.48K
--
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
5.30K
+16.66%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
4.96K
--
Ms. Sandra Dillard van Der Vaart
Ms. Sandra Dillard van Der Vaart
Executive Vice President, Chief Legal Officer, and Corporate Secretary
Executive Vice President, Chief Legal Officer, and Corporate Secretary
3.78K
+109.19%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
105.07K
+19.15%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
32.07K
+10.11%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
13.17K
-5.65%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Desglose de ingresos
Divisa: USDHora de actualización: mié., 12 de mar
Divisa: USDHora de actualización: mié., 12 de mar
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: dom., 27 de abr
Hora de actualización: dom., 27 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
11.49%
BlackRock Institutional Trust Company, N.A.
5.43%
State Street Global Advisors (US)
4.43%
Geode Capital Management, L.L.C.
2.40%
Diamond Hill Capital Management Inc.
2.35%
Other
73.90%
Estadísticas de accionistas
Accionista
Proporción
The Vanguard Group, Inc.
11.49%
BlackRock Institutional Trust Company, N.A.
5.43%
State Street Global Advisors (US)
4.43%
Geode Capital Management, L.L.C.
2.40%
Diamond Hill Capital Management Inc.
2.35%
Other
73.90%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
44.24%
Investment Advisor
41.43%
Hedge Fund
3.71%
Research Firm
2.25%
Pension Fund
1.99%
Bank and Trust
1.53%
Sovereign Wealth Fund
1.31%
Individual Investor
0.40%
Family Office
0.05%
Other
3.09%
Participación institucional
Hora de actualización: lun., 20 de ene
Hora de actualización: lun., 20 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
1796
81.55M
97.46%
-4.03M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
2023Q3
1930
84.34M
99.29%
-7.18M
2023Q2
1934
84.05M
94.75%
-3.56M
2023Q1
1940
82.33M
92.89%
-5.93M
2022Q4
1948
82.50M
93.48%
-7.69M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
9.62M
11.49%
+15.33K
+0.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
4.55M
5.43%
-7.51K
-0.16%
Dec 31, 2024
State Street Global Advisors (US)
3.70M
4.43%
-23.02K
-0.62%
Dec 31, 2024
Geode Capital Management, L.L.C.
2.00M
2.4%
+39.26K
+2.00%
Dec 31, 2024
Diamond Hill Capital Management Inc.
1.97M
2.35%
-11.59K
-0.59%
Dec 31, 2024
Allspring Global Investments, LLC
1.92M
2.29%
+51.05K
+2.74%
Dec 31, 2024
BlackRock Financial Management, Inc.
1.92M
2.3%
-131.53K
-6.40%
Dec 31, 2024
Select Equity Group, L.P.
1.60M
1.91%
+959.98K
+150.95%
Dec 31, 2024
Citadel Advisors LLC
1.43M
1.71%
+1.30M
+968.69%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
1.36M
1.63%
-4.00K
-0.29%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Global X Telemedicine & Digital Health ETF
3.99%
iShares U.S. Healthcare Providers ETF
3.06%
iShares Large Cap Value Active ETF
2.38%
Thrivent Small-Mid Cap ESG ETF
2.01%
SPDR S&P Health Care Services ETF
1.96%
Invesco S&P 500 Equal Weight Health Care ETF
1.73%
SRH US Quality ETF
1.7%
Brandes US Value ETF
1.44%
WisdomTree BioRevolution Fund
1.37%
Schwab Ariel ESG ETF
1.25%
Ver más
Global X Telemedicine & Digital Health ETF
Proporción3.99%
iShares U.S. Healthcare Providers ETF
Proporción3.06%
iShares Large Cap Value Active ETF
Proporción2.38%
Thrivent Small-Mid Cap ESG ETF
Proporción2.01%
SPDR S&P Health Care Services ETF
Proporción1.96%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.73%
SRH US Quality ETF
Proporción1.7%
Brandes US Value ETF
Proporción1.44%
WisdomTree BioRevolution Fund
Proporción1.37%
Schwab Ariel ESG ETF
Proporción1.25%
Dividendos
Un total de
692.30M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Jan 09, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Oct 12, 2023
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
Nov 08, 2023
Dec 12, 2023
Nov 07, 2023
Jul 13, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
Aug 08, 2023
Sep 08, 2023
Aug 07, 2023
Apr 06, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Jan 12, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2023 going ex on Feb 22, 2023
Feb 23, 2023
Mar 13, 2023
Feb 22, 2023
Oct 12, 2022
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 09, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 09, 2022
Nov 16, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos